Skip to content
Screener

CytomX Therapeutics CTMX Return on invested capital

Return on invested capital at other companies

Pfizer logo
PfizerPFE
6%
Amgen logo
AmgenAMGN
14.8%+3.6pp
Janux Therapeutics logo
Janux TherapeuticsJANX
-15.3%-1.9pp
Immunome logo
ImmunomeIMNM
-746.6%+212pp
Arcus Biosciences logo
Arcus BiosciencesRCUS
-116%+139pp
Vir Biotechnology, Inc. logo
Vir Biotechnology, Inc.VIR
-36.6%-10.5pp

Other financials

Income statement

See full
Revenue$1.4M-92.4%
Operating income-$23.8M-1,749%
Net income-$20.7M-13,319%
EPS (diluted)-$0.09

Balance sheet

See full
Cash & equivalents$17.2M-64.9%
Total debt$5.7M-17.2%
Total equity$302.1M+152%
Total assets$381.2M+118%

Cash flow

See full
Operating cash flow-$18.1M-14.7%
CapEx--100%
Free cash flow-$18.1M-14.5%

Valuation

See full
Market cap$733.66M+115%
Enterprise value$722.14M+141%
P/S40.1×+37.7×

Profitability

See full
Operating margin-476.2%-507pp
Net margin-435.2%-469pp
FCF margin-450.7%-524pp

Returns & leverage

See full
Return on equity-37.8%
Debt / equity0.0×
Current ratio9.4×+5.2×

Where this comes from

Calculated from CytomX Therapeutics’s reported figures.

Based on trailing twelve months.

The source filing: CytomX Therapeutics’s 10-Q, filed August 6, 2026. Open the filing →

Filed
Aug 6, 2026, 4:05 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-337950

FAQ

What is CytomX Therapeutics's return on invested capital?
CytomX Therapeutics (CTMX) reported return on invested capital of -47.3% in Q2 2026.
What does return on invested capital mean?
Net operating profit after tax (operating income taxed at the effective rate) divided by average invested capital (debt plus equity minus cash). Measures the after-tax return on all capital put to work in the business, independent of capital structure.

Ask your AI about CytomX Therapeutics's return on invested capital.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude